
Joseph R Leventhal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7949420/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Establishment of Durable Chimerism with Minimal GvHD in Highly Mismatched Recipients Receiving an Investigational Facilitated Allo-HSCT. Transplantation and Cellular Therapy, 2022, 28, S74-S75.	0.6	о
2	Pre-transplant infusion of donor leukocytes treated with extracorporeal photochemotherapy induces immune hypo-responsiveness and long-term allograft survival in murine models. Scientific Reports, 2022, 12, 7298.	1.6	4
3	The Fourth International Workshop on Clinical Transplant Tolerance. American Journal of Transplantation, 2021, 21, 21-31.	2.6	28
4	Chimerism and tolerance: past, present and future strategies to prolong renal allograft survival. Current Opinion in Nephrology and Hypertension, 2021, 30, 63-74.	1.0	12
5	Tackling Chronic Kidney Transplant Rejection: Challenges and Promises. Frontiers in Immunology, 2021, 12, 661643.	2.2	45
6	Renal allograft function in kidney transplant recipients infected with SARS-CoV 2: An academic single center experience. PLoS ONE, 2021, 16, e0252979.	1.1	7
7	Arguments against the Requirement of a Biological License Application for Human Pancreatic Islets: The Position Statement of the Islets for US Collaborative Presented during the FDA Advisory Committee Meeting. Journal of Clinical Medicine, 2021, 10, 2878.	1.0	3
8	Bone marrow-derived AXL tyrosine kinase promotes mitogenic crosstalk and cardiac allograft vasculopathy. Journal of Heart and Lung Transplantation, 2021, 40, 435-446.	0.3	4
9	Establishment of Durable Chimerism with Minimal GvHD in Highly Mismatched Recipients Receiving an Investigational Facilitated Allo-HSCT. Blood, 2021, 138, 911-911.	0.6	2
10	Outstanding questions in transplantation: Tolerance. American Journal of Transplantation, 2020, 20, 348-354.	2.6	19
11	Antigen Specificity Enhances Disease Control by Tregs in Vitiligo. Frontiers in Immunology, 2020, 11, 581433.	2.2	34
12	Cell therapy can enable minimization of immunosuppression. Nature Reviews Nephrology, 2020, 16, 486-487.	4.1	1
13	Achieving Solid Organ Transplant Tolerance: New Findings, More Questions and the Search Continues. Transplantation, 2020, 104, 1531-1532.	0.5	Ο
14	HLA MOLECULAR MISMATCH ANALYSIS IN PATIENTS RECEIVING KIDNEY AND THE HEMATOPOIETIC STEM / FACILITATING CELL INDUCTION PROTOCOL. Transplantation, 2020, 104, S50-S50.	0.5	0
15	DIAGNOSIS OF KIDNEY TRANSPLANT REJECTION BY TRACKING DONOR-REACTIVE T-CELL CLONES IN THE POST-TRANSPLANT BIOPSY, BLOOD AND URINE SAMPLES. Transplantation, 2020, 104, S30-S30.	0.5	Ο
16	Prognosis and Outcomes of Patients with Post-Transplant Lymphoproliferative Disorder: A Single Center Retrospective Review. Blood, 2020, 136, 9-10.	0.6	3
17	Summary of the Third International Workshop on Clinical Tolerance. American Journal of Transplantation, 2019, 19, 324-330.	2.6	29
18	Varying levels of X chromosome coalescence in female somatic cells alters the balance of X-linked dosage compensation and is implicated in female-dominant systemic lupus erythematosus. Scientific Reports, 2019, 9, 8011	1.6	5

#	Article	IF	CITATIONS
19	Mechanistic analyses in kidney transplant recipients prospectively randomized to two steroid free regimen—Low dose Tacrolimus with Everolimus versus standard dose Tacrolimus with Mycophenolate Mofetil. PLoS ONE, 2019, 14, e0216300.	1.1	9
20	Transcriptomic studies in tolerance: Lessons learned and the path forward. Human Immunology, 2018, 79, 395-401.	1.2	6
21	Cellular and functional biomarkers of clinical transplant tolerance. Human Immunology, 2018, 79, 322-333.	1.2	10
22	Updated follow-up of a tolerance protocol in HLA-identical renal transplant pairs given donor hematopoietic stem cells. Human Immunology, 2018, 79, 277-282.	1.2	18
23	Generation and Characterization of Alloantigen-Specific Regulatory T Cells For Clinical Transplant Tolerance. Scientific Reports, 2018, 8, 1136.	1.6	38
24	Clinical transplant tolerance: Coming of age. Human Immunology, 2018, 79, 255-257.	1.2	8
25	Tolerance induction in HLA disparate living donor kidney transplantation by facilitating cell-enriched donor stem cell Infusion: The importance of durable chimerism. Human Immunology, 2018, 79, 272-276.	1.2	47
26	Intragraft Molecular Pathways Associated with Tolerance Induction in Renal Transplantation. Journal of the American Society of Nephrology: JASN, 2018, 29, 423-433.	3.0	11
27	Long-term Follow-up of a Phase 2 Clinical Trial to Induce Tolerance in Living Donor Renal Transplant Recipients. Transplantation, 2018, 102, S394.	0.5	1
28	Abdominal pain and vomiting in a pancreas transplant recipient. American Journal of Transplantation, 2018, 18, 2362-2364.	2.6	0
29	A Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T cells in Living Donor Kidney Transplants. Scientific Reports, 2018, 8, 7428.	1.6	178
30	Use of a Processed Hematopoietic Stem Cell Product (FCRx) in Unmatched Related and Unrelated Donor — Recipient Pairs Is Associated with High Levels of Donor Chimerism and Donor-Specific Tolerance to Kidney Allografts. Blood, 2018, 132, 202-202.	0.6	0
31	Cell Therapy in Kidney Transplantation: Focus on Regulatory T Cells. Journal of the American Society of Nephrology: JASN, 2017, 28, 1960-1972.	3.0	26
32	Delayed Donor Bone Marrow Infusion Induces Liver Transplant Tolerance. Transplantation, 2017, 101, 1056-1066.	0.5	15
33	HSCT-Based Approaches for Tolerance Induction in Renal Transplant. Transplantation, 2017, 101, 2682-2690.	0.5	21
34	Immunoregulatory Effects of Everolimus on In Vitro Alloimmune Responses. PLoS ONE, 2016, 11, e0156535.	1.1	11
35	Differential Effects of Calcineurin and Mammalian Target of Rapamycin Inhibitors on Alloreactive Th1, Th17, and Regulatory T Cells. Transplantation, 2015, 99, 1774-1784.	0.5	51
36	Facilitating cells in tolerance induction for kidney transplantation. Current Opinion in Organ Transplantation, 2015, 20, 57-63.	0.8	12

#	Article	IF	CITATIONS
37	Facilitating cells: Translation of hematopoietic chimerism to achieve clinical tolerance. Chimerism, 2015, 6, 33-39.	0.7	11
38	Cellular and molecular immune profiles in renal transplant recipients after conversion from tacrolimus to sirolimus. Kidney International, 2015, 87, 828-838.	2.6	28
39	Clinical Implications of Basic Science Discoveries: Induced Pluripotent Stem Cell Therapy in Transplantation—A Potential Role for Immunologic Tolerance. American Journal of Transplantation, 2015, 15, 887-890.	2.6	5
40	Immune Reconstitution/Immunocompetence in Recipients of Kidney Plus Hematopoietic Stem/Facilitating Cell Transplants. Transplantation, 2015, 99, 288-298.	0.5	122
41	Defining the Alloreactive T Cell Repertoire Using High-Throughput Sequencing of Mixed Lymphocyte Reaction Culture. PLoS ONE, 2014, 9, e111943.	1.1	41
42	Epitope Analysis of HLA-DQ Antigens. Transplantation, 2014, 98, 157-166.	0.5	68
43	OR26. Human Immunology, 2014, 75, 21.	1.2	0
44	P011. Human Immunology, 2014, 75, 56.	1.2	0
45	Immune Reconstitution in Recipients of Living Donor Kidney/Hematopoietic Stem + Facilitating Cell Transplants. Blood, 2014, 124, 191-191.	0.6	1
46	Systemic immunoregulatory and proteogenomic effects of tacrolimus to sirolimus conversion in liver transplant recipients. Hepatology, 2013, 57, 239-248.	3.6	52
47	Genomic Biomarkers Correlate with HLA-Identical Renal Transplant Tolerance. Journal of the American Society of Nephrology: JASN, 2013, 24, 1376-1385.	3.0	60
48	Tolerance Induction in HLA Disparate Living Donor Kidney Transplantation by Donor Stem Cell Infusion. Transplantation, 2013, 95, 169-176.	0.5	143
49	HLA-DQ Barrier. Transplantation, 2013, 96, 1065-1072.	0.5	29
50	The DQ Barrier. Transplantation, 2013, 95, 635-640.	0.5	43
51	Evaluation Of Immunocompentence In Tolerant Chimeric Recipients Of Hematopoietic Stem Cell/Renal Transplants. Blood, 2013, 122, 4483-4483.	0.6	0
52	Update On Phase 2 Clinical Trial To Induce Tolerance In Mismatched Living Donor Renal Transplant Recipients. Blood, 2013, 122, 4622-4622.	0.6	0
53	Chimerism and Tolerance Without Gvhd In Mismatched Recipients Of Combined Hematopoietic Stem Cell/Kidney Transplants: Donor-Specific Hyporeactivity Is Not a Reliable Biomarker For Tolerance. Blood, 2013, 122, 912-912.	0.6	2
54	Resolution of Recurrent Focal Segmental Glomerulosclerosis after Retransplantation. New England Journal of Medicine, 2012, 366, 1648-1649.	13.9	157

#	Article	IF	CITATIONS
55	Long-Term Kidney Allograft Function and Survival in Prednisone-Free Regimens. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 504-512.	2.2	44
56	Favorable effects of alemtuzumab on allospecific regulatory T-cell generation. Human Immunology, 2012, 73, 141-149.	1.2	19
57	Chimerism and Tolerance Without GVHD or Engraftment Syndrome in HLA-Mismatched Combined Kidney and Hematopoietic Stem Cell Transplantation. Science Translational Medicine, 2012, 4, 124ra28.	5.8	376
58	Microchimerism in promoting graft acceptance in clinical transplantation. Current Opinion in Organ Transplantation, 2011, 16, 345-352.	0.8	8
59	Is durable macrochimerism key to achieving clinical transplantation tolerance?. Current Opinion in Organ Transplantation, 2011, 16, 343-344.	0.8	8
60	Allospecific Regulatory Effects of Sirolimus and Tacrolimus in the Human Mixed Lymphocyte Reaction. Transplantation, 2011, 91, 199-206.	0.5	34
61	Requirement of Cognate CD4+ T-Cell Recognition for the Regulation of Allospecific CTL by Human CD4+CD127â^'CD25+FOXP3+ Cells Generated in MLR. PLoS ONE, 2011, 6, e22450.	1.1	3
62	Durable Chimerism, Absence of Graft-Versus-Host Disease and the Induction of Donor Specific Tolerance in Recipients of HLA Disparate Living Donor Kidney Transplants and Therapeutic Cell Transfer. Blood, 2011, 118, 832-832.	0.6	0
63	Chimerism, Lymphocyte Recovery, and the Absence of Graft-Versus-Host Disease in Recipients of Mismatched Unrelated Combined Kidney and HSC Transplants for Tolerance Induction. Blood, 2011, 118, 1969-1969.	0.6	0
64	The Complexity of Human Leukocyte Antigen (HLA)-DQ Antibodies and Its Effect on Virtual Crossmatching. Transplantation, 2010, 90, 1117-1124.	0.5	75
65	Late conversion of tacrolimus to sirolimus in a prednisoneâ€free immunosuppression regimen in renal transplant patients. Clinical Transplantation, 2010, 24, 199-206.	0.8	2
66	A decade of minimally invasive donation: experience with more than 1200 laparoscopic donor nephrectomies at a single institution. Clinical Transplantation, 2010, 24, 169-174.	0.8	46
67	Ureteral Complications in the Era of Laparoscopic Living Donor Nephrectomy: Do We Need to Preserve the Gonadal Vein with the Specimen?. Journal of Endourology, 2010, 24, 247-251.	1.1	16
68	The Human "Treg MLR― Immune Monitoring for FOXP3+ T Regulatory Cell Generation. Transplantation, 2009, 88, 1303-1311.	0.5	36
69	Two Rare Forms of Renal Allograft Glomerulopathy During Cytomegalovirus Infection and Treatment. American Journal of Kidney Diseases, 2008, 51, 1047-1051.	2.1	3
70	Tailoring Antibody Testing and How to Use it in the Calculated Panel Reactive Antibody Era: The Northwestern University Experience. Transplantation, 2008, 86, 1052-1059.	0.5	24
71	Leukopenia Complicates Cytomegalovirus Prevention After Renal Transplantation With Alemtuzumab Induction. Transplantation, 2007, 83, 874-882.	0.5	37
72	Long-Term Renal Transplant Function in Recipient of Simultaneous Kidney and Pancreas Transplant Maintained With Two Prednisone-Free Maintenance Immunosuppressive Combinations: Tacrolimus/Mycophenolate Mofetil Versus Tacrolimus/Sirolimus. Transplantation, 2007, 83, 1324-1329.	0.5	41

#	Article	IF	CITATIONS
73	Laparoscopic Living Donor Nephrectomy: A Single-Center Sequential Experience Comparing Hand-Assisted Versus Standard Technique. Urology, 2007, 70, 1060-1063.	0.5	37
74	Reply to 'Critics slam Russian trial to test pig pancreas for diabetes'. Nature Medicine, 2007, 13, 662-663.	15.2	7
75	Proposed classification of complications after live donor nephrectomy. Urology, 2006, 67, 927-931.	0.5	86
76	Targeting Acute Allograft Rejection by Immunotherapy With Ex Vivo-Expanded Natural CD4+CD25+ Regulatory T Cells. Transplantation, 2006, 82, 1749-1755.	0.5	58
77	Radiotherapy for Rejection of Renal Transplant Allografts Refractory to Medical Immunosuppression. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 551-554.	0.6	7
78	Clinical trial of islet xenotransplantation in Mexico. Xenotransplantation, 2006, 13, 371-372.	1.6	18
79	Effect of Prednisone versus No Prednisone as Part of Maintenance Immunosuppression on Long-Term Renal Transplant Function. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 1029-1038.	2.2	33
80	Effect of glucose toxicity on intraportal tilapia islet xenotransplantation in nude mice. Xenotransplantation, 2005, 12, 189-196.	1.6	16
81	Reduction of CMV Disease with Steroid-Free Immunosuppresssion in Simultaneous Pancreas-Kidney Transplant Recipients. American Journal of Transplantation, 2005, 5, 1423-1429.	2.6	67
82	Alemtuzumab Induction and Prednisone-Free Maintenance Immunotherapy in Kidney Transplantation: Comparison with Basiliximab Induction-Long-Term Results. American Journal of Transplantation, 2005, 5, 2539-2548.	2.6	178
83	Piscine Islet Xenotransplantation. ILAR Journal, 2004, 45, 314-323.	1.8	20
84	Evidence that tilapia islets do not express alpha-(1,3)gal: implications for islet xenotransplantation. Xenotransplantation, 2004, 11, 276-283.	1.6	8
85	Laparoscopic donor nephrectomy 1997 to 2003: Lessons learned with 500 cases at a single institution. Surgery, 2004, 136, 881-890.	1.0	129
86	Xenotransplant News. Xenotransplantation, 2003, 10, 95-95.	1.6	0
87	Pretransplant Evaluation of Renal Transplant Candidates. Seminars in Nephrology, 2002, 22, 515-525.	0.6	30
88	A PROSPECTIVE STUDY OF RAPID CORTICOSTEROID ELIMINATION IN SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATION. Transplantation, 2002, 73, 169-177.	0.5	134
89	Sequential Kidney/Islet Transplantation Using Prednisone-Free Immunosuppression. American Journal of Transplantation, 2002, 2, 674-677.	2.6	44
90	Surgical techniques in right laparoscopic donor nephrectomy1 1No competing interests declared Journal of the American College of Surgeons, 2002, 195, 131-137.	0.2	41

#	Article	IF	CITATIONS
91	RISK FACTORS AND IMPACT OF CYTOMEGALOVIRUS DISEASE IN SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATION. Transplantation, 2001, 72, 1940-1945.	0.5	48
92	Are Concerns Over Right Laparoscopic Donor Nephrectomy Unwarranted?. Annals of Surgery, 2001, 233, 645-651.	2.1	110
93	Transplanting a Kidney with a Renal Artery Aneurysm. Vascular Surgery, 2001, 35, 321-324.	0.3	6
94	SYNTHETIC PEPTIDES WHICH INHIBIT THE INTERACTION BETWEEN C1q AND IMMUNOGLOBULIN AND PROLONG XENOGRAFT SURVIVAL1. Transplantation, 2000, 70, 828-836.	0.5	23
95	KIDNEY TRANSPLANTATION WITHOUT PREDNISONE Transplantation, 2000, 69, S133.	0.5	14
96	LAPAROSCOPIC LIVE DONOR NEPHRECTOMY???IS IT SAFE?. Transplantation, 2000, 70, 602-606.	0.5	117
97	ALTERED INFECTIVITY OF PORCINE ENDOGENOUS RETROVIRUS BY "PROTECTIVE―AVIAN ANTIBODIES: IMPLICATIONS FOR PIG-TO-HUMAN XENOTRANSPLANTATION Transplantation, 2000, 69, S418.	0.5	0
98	ALLOGENEIC TRANSPLANTATION INDUCES HCMV IMMEDIATE EARLY GENE EXPRESSION AND ACTIVATES NFκB Transplantation, 2000, 69, S385.	0.5	0
99	lgY antiporcine endothelial cell antibodies effectively block human antiporcine xenoantibody binding. Xenotransplantation, 1999, 6, 98-109.	1.6	38
100	LOW BIOAVAILABILITY OF CYCLOSPORINE MICROEMULSION AND TACROLIMUS IN A SMALL BOWEL TRANSPLANT RECIPIENT. Transplantation, 1999, 67, 333-335.	0.5	55
101	MYCOPHENOLATE MOFETIL AND TACROLIMUS AS PRIMARY MAINTENANCE IMMUNOSUPPRESSION IN SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATION. Transplantation, 1999, 67, 586-593.	0.5	63
102	ALLOGENEIC TRANSPLANTATION OF LATENTLY INFECTED KIDNEYS INDUCES EXPRESSION OF MCMV LYTIC REPLICATION CYCLE GENES IN VIVO. Transplantation, 1999, 67, S604.	0.5	0
103	The emergence of xenotransplantation. Transplant Immunology, 1995, 3, 21-31.	0.6	19
104	Antibody Removal by Column Immunoabsorption Prevents Tissue Injury in an Ex Vivo Model of Pig-to-Human Xenograft Hyperacute Rejection. Journal of Surgical Research, 1995, 59, 43-50.	0.8	32
105	Beyond Hyperacute Rejection. Transplantation, 1995, 59, 171-176.	0.5	2
106	Cellular rejection in discordant xenografts when hyperacute rejection is prevented: analysis using adoptive and passive transfer. Transplant Immunology, 1994, 2, 87-93.	0.6	39
107	EVIDENCE THAT RAT XENOREACTIVE ANTIBODIES RECOGNIZE MULTIPLE PROTEIN ANTIGENS ON GUINEA PIG ENDOTHELIAL CELLS AND PLATELETS. Transplantation, 1994, 58, 458-466.	0.5	13
108	THE IMMUNOPATHOLOGY OF CARDIAC XENOGRAFT REJECTION IN THE GUINEA PIG-TO-RAT MODEL. Transplantation, 1993, 56, 1-8.	0.5	188

#	Article	IF	CITATIONS
109	EVIDENCE THAT 15-DEOXYSPERGUALIN INHIBITS NATURAL ANTIBODY PRODUCTION BUT FAILS TO PREVENT HYPERACUTE REJECTION IN A DISCORDANT XENOGRAFT MODEL. Transplantation, 1992, 54, 26-31.	0.5	53